Clinical Trials
3 trialsNCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04165031 2021-11-24
A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation
Eli Lilly and Company
Phase 1/2 Terminated
NCT02745769 2019-03-05
A Study in Advanced Cancers Using Ramucirumab (LY3009806) and Other Targeted Agents
Eli Lilly and Company
Phase 1 Completed